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Abstract
Polymorphic parasite antigens are known targets of protective immunity to malaria, but this antigenic variation poses
challenges to vaccine development. A synthetic MSP-1 Block 2 construct, based on all polymorphic variants found in natural
Plasmodium falciparum isolates has been designed, combined with the relatively conserved Block 1 sequence of MSP-1 and
expressed in E.coli. The MSP-1 Hybrid antigen has been produced with high yield by fed-batch fermentation and purified
without the aid of affinity tags resulting in a pure and extremely thermostable antigen preparation. MSP-1 hybrid is
immunogenic in experimental animals using adjuvants suitable for human use, eliciting antibodies against epitopes from all
three Block 2 serotypes. Human serum antibodies from Africans naturally exposed to malaria reacted to the MSP-1 hybrid as
strongly as, or better than the same serum reactivities to individual MSP-1 Block 2 antigens, and these antibody responses
showed clear associations with reduced incidence of malaria episodes. The MSP-1 hybrid is designed to induce a protective
antibody response to the highly polymorphic Block 2 region of MSP-1, enhancing the repertoire of MSP-1 Block 2 antibody
responses found among immune and semi-immune individuals in malaria endemic areas. The target population for such a
vaccine is young children and vulnerable adults, to accelerate the acquisition of a full range of malaria protective antibodies
against this polymorphic parasite antigen.
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Introduction
Antibody responses to polymorphic parasite antigens of
Plasmodium falciparum are associated with protective immunity to
malaria [1,2,3,4,5]. There is evidence that selective pressure by the
human immune system may be responsible for the evolution and
maintenance of such polymorphism [6,7,8]. Protective natural
immunity to malaria develops only after repeated infection [9,10],
suggesting that exposure to different variants of polymorphic
antigens may be required to develop a repertoire of variant
antibodies before adequate protection can be achieved [11]. The
development of vaccines against protective but polymorphic
antigens would accelerate the acquisition of a broad immune
repertoire, particularly in infants, young children and other
specific vulnerable groups. It seems likely that selective immune
pressure on antigens which elicit antibodies most threatening to
the parasite’s survival has driven the evolution and maintenance of
this polymorphism [8].
Merozoite surface protein 1 (MSP-1) is the most abundant
surface component of the merozoite stage of the parasite life cycle,
making up 40% of the GPI-anchored merozoite surface protein
coat [12,13,14]. MSP-1 is accessible to the host immune system,
since it remains on the surface of the merozoite while it is free of
the host erythrocyte [15]. Monoclonal antibodies raised against
the MSP-1 molecule specifically recognize all forms of the
erythrocyte stages of the parasite [16,17,18], and MSP-1 is likely
to be a target of cytotoxic T cell responses due to its expression in
hepatic liver schizonts [19,20]. An N-terminal region of MSP-1,
known as Block 2, is by far the most polymorphic region of the
molecule, with hundreds of known variant sequences from globally
diverse parasite isolates [21,22]. Several sero-epidemiological
studies have shown that antibodies to Block 2 are associated with
reduced risk of clinical malaria episodes [3,7,23,24]. Other parts of
the MSP-1 molecule, such as MSP-119 showed little or no such
association with protection [25,26]. The immune response to
Block 2 is almost exclusively of the IgG3 subclass unlike the
response directed to MSP119, where the predominant subclass is
IgG1 [27,28]. In vitro ADCI assays with purified IgG3 from
immune individuals (including antibodies to MSP-1 Block 2) have
shown the importance of this subclass as an inhibitor of parasite
growth [29,30], supporting the hypothesis that antigens that elicit
IgG3 responses (such as MSP-1 Block 2 and MSP-2) are important
targets of protective mechanisms [31,32].
In an in vivo non-human primate model, we have demonstrated
that immunization of highly susceptible Aotus lemurinus griseimembra
monkeys with a Block 2 GST fusion protein can elicit immune
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animals using a human compatible adjuvant (Cavanagh et al.,
manuscript in preparation). Significantly, parasite-reactive (i.e.
IFA) anti-Block 2 antibody titers were the strongest predictor of
protection in this study. Furthermore, the animals that controlled
their parasitaemia recognised a larger number of peptide epitopes
within Block 2 compared to the non-protected animals. Both these
lines of evidence suggest that the Block 2 region of MSP-1 is a
target of protective immunity against P. falciparum and thus a
promising candidate for the development of a malaria vaccine
antigen.
Sequence analysis of more than 100 variants of the MSP-1
Block 2 sequence in naturally occurring P. falciparum isolates, and
epitope mapping of natural antibody response to Block 2 in
humans showed that despite their extreme polymorphism, there
are 3 basic serotypes of Block 2, named after representative clones
from each serotype as the K1, MAD20 and RO33 types. Within
both the K1 and MAD20 serotypes there are semi-conserved
flanking sequences, which enclose extremely polymorphic repet-
itive sequences [21,22,33]. These repeat sequences comprise
tripeptide repeat patterns that are unique to each serotype. By
contrast the RO33 serotype is largely conserved but has a limited
number of point mutations [21,22]. In this study a synthetic gene
has been constructed comprising all the known polymorphic
sequences for each of the three serotypes, in an arrangement
similar to that of the naturally occurring Block 2 alleles, creating a
construct longer than any known natural allele, but incorporating
the majority of known antigenic and sequence diversity in Block 2
(Fig. 1). Combining multiple serotypes of such a polymorphic
region of MSP-1 would therefore allow the induction of antibody
responses to multiple Block 2 serotypes by administration of a
single polypeptide, combining known human T cell and B cell
epitopes.
In earlier work, we showed that MSP-1 Block 2 was
immunogenic in mice when formulated with Alum, and fused to
the carrier protein GST [33]. However, an individual Block 2
antigen (P. falciparum strain FVO Block 2) when expressed as a
recombinant protein in E. coli, proved to be weakly immunogenic,
using a variety of adjuvants (Fig. S1). This is probably due to the
lack of T cell epitopes within these highly polymorphic Block 2
sequences, which are made up of hydrophilic, polar residues not
commonly found within MHC binding motifs. However, there is
strong published evidence from other groups that human and
mouse T-cell epitopes exist in Block 1 of MSP-1, as well as in the
junction between Block 1 and Block 2 [34,35]. Quakyi et al [34]
reported that one highly conserved peptide within MSP-1 Block 1
(VTHESYQELVKKLEALEDAV) was recognised by human T
cell clones which secreted IFNc and proliferated. Subsequently,
Parra at al [35] showed that this T cell epitope and an adjacent
epitope were able to induce MSP-1-specific cellular and humoral
immune responses when injected into mice. Therefore, to improve
immunogenicity by incorporating cognate T cell help, we added
the Block 1 sequence to the synthetic Block 2 construct, thus
reconstructing these two epitopes. This synthetic MSP-1 Block 1/
Block 2 construct (referred to as MSP-1 hybrid) was designed
without affinity tags and then codon-optimised for expression in E.
coli (Fig. 1).
This MSP-1 hybrid antigen, together with a suitable adjuvant, is
designed to produce a vaccine that will induce protective antibody
responses to polymorphic MSP-1 Block 2 sequences, replicating
the network of responses found among immune and semi-immune
adults in malaria endemic areas. The target population for such a
vaccine is therefore primarily young children and vulnerable
adults who do not produce a broad range of protective antibodies
to P. falciparum. Vaccines such as the MSP-1 hybrid may also be
useful for boosting and broadening the immune responses in
individuals who already make limited, serotype-specific responses
to Block 2.
Results
Expression and purification of MSP-1 hybrid
The DNA sequence of the MSP-1 hybrid was codon optimized
for expression in E. coli. The original coding sequence was sent to
GeneArt AG, Regensburg, Germany, and optimized using the
company’s GeneOptimizerH software. The codon-optimized
sequence contained no purification tag sequences, and consisted
entirely of MSP-1-derived sequences, with the single amino acid
addition of an N-terminal methionine initation codon. The
synthesized gene was then cloned into the pET24a expression
vector (Novagen, UK) and expressed in BLR(DE3)pLysS cells.
Pilot expression tests were carried out to establish optimal small-
scale expression conditions. Expression and induction conditions
were modified, with cell growth at 30uC in Luria-Bertani medium
containing 1% glucose and induction at 25uC with 1 mM IPTG
for 4 h. This protocol resulted in high level expression of MSP-1
hybrid on induction as a soluble protein at ,55 kDa in the cell
lysate (Fig. 2A). The identity of the protein was confirmed by
Western blotting using a mouse monoclonal specific for the K1
Block 2 serotype of MSP-1 (mAb12.2, Fig. 2B) [33] and with
polyclonal sera raised against individual MSP-1 Block 2
recombinant proteins [33] (data not shown). The major soluble
protein in the cell lysate was MSP-1 hybrid, with minor
degradation products as detected by mAb 12.2 reactivity
(Fig. 2B, Lane 2). In 1-liter shaking-flask culture, MSP-1 hybrid
accounted for an estimated 15% of the total soluble protein, as
assessed by densitometry of silver stained gels. The first
purification step (70uC heating of cell lysate) eliminated the
majority of host protein contaminants from the product, yielding a
,80% pure product, equivalent to ,210 mg L
21 cell culture.
After dialysis against 25 mM Tris pH 8.0, and further purification
by anion exchange chromatography, pure MSP-1 hybrid product
(.97%) was obtained with a yield of 197.6 mg L
21 cell culture.
When fractions from each purification step were probed by
Figure 1. Schematic representation of the MSP-1 hybrid vaccine construct, based on the polymorphic N-terminal region of MSP-1.
The construct encodes the N-terminal MSP-1 Block 1 region, the K1 Block 2 synthetic sequence, the RO33 Block 2 sequence and the MAD20 Block 2
synthetic sequence of MSP-1 of P. falciparum. Synthetic Block 2 repeat sequences of the K1 and MAD20 serotypes are indicated by vertical and
diagonal hatched markings respectively.
doi:10.1371/journal.pone.0026616.g001
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degradation species of the MSP-1 hybrid could be detected, but
these were not visible on the equivalent silver-stained gel (Fig. 2A
and 2B; lane 7).
This expression and purification process was easily transferred
to 10-liter fermentor scale and to high density culture as described
in Materials and Methods, with no loss of efficiency and/or
protein yields (Table 1). During fermentor scale expression of the
MSP-1 hybrid, there were no problems with plasmid stability or
expression, despite the fact that the MSP-1 hybrid gene contains
repetitive sequences, which have been reported to be problematic
to express in E. coli [36]. Plasmid DNA from individual colonies,
grown from harvested fermentor cell paste, contained identical
MSP-1 hybrid sequences to the starter culture colonies (data not
shown). The protein product does not appear to be toxic to cells,
as fermentor cell growth continued after induction of protein
expression with IPTG.
Fermentor batch yields and purity of product were comparable
with those obtained in shaking flask culture, with a final product
containing no detectable contaminating proteins by silver staining
of SDS-PAGE gels or by mass spectrometry (Fig. 2 and 3B).
Highly pure (.97%) MSP-1 hybrid was recovered with a yield of
550 mg L
21 cell culture. Yields and purity of the purified product
at each purification step from fed-batch fermentor studies are
summarized in Table 1.
Characteristics and stability of MSP-1 hybrid
The MSP-1 hybrid protein was found to have some atypical
biochemical properties that are however characteristic of intrin-
sically unstructured proteins. MSP-1 hybrid migrated on standard
reducing SDS-PAGE at ,55 kDa, approximately twice both its
predicted molecular mass (30,987 Da) and that determined
experimentally by mass spectrometry (31,113 Da) (Fig. 2A).
MSP-1 hybrid stained very weakly with Coomassie Brilliant Blue,
but strongly with silver nitrate. The MSP-1 hybrid protein was
observed to remain soluble in isotonic salt buffers at temperatures
between 70uC–90uC. Remarkably, the purified MSP-1 hybrid
antigen can be stored at ambient temperature without significant
degradation. Purified MSP-1 hybrid was heat-treated at 70uC for
20 minutes, and then incubated at 25uC for 60 days. No
significant breakdown of the protein was observed on SDS-PAGE
gels (Fig. 3A). Sensitive analysis by mass spectrometry of samples
taken before and after incubation at room temperature again
showed only trace degradation, with some increased Mr species
caused by salt adducts formed on prolonged incubation (Fig. 3B).
Several monoclonal antibodies specific for individual serotypes of
Figure 2. Analysis of protein expression and purification by gel electrophoresis and Western blotting. A. Samples from cell growth and
purification steps were resolved by SDS-PAGE and silver stained. Cells harvested after induction of protein expression (lane 2) were lysed as described
and subject to a two step purification process to obtain a final pure product. Lane 1, pre-induction cells; lane 2 post-induction cells; lane 3, soluble
clarified cell lysate; lane 4 heat treated and clarified cell lysate; lane 5, dialysed pre-AEX sample; lane 6 Capto-Q flow through; lane 7, purified MSP-1
hybrid. B. Samples from cell growth and purification steps were resolved by SDS-PAGE and characterised by Western blotting. A nitrocellulose
membrane blotted from an identically loaded gel to that shown in Panel A was probed with a monoclonal antibody specific for MSP-1 Block 2 (mAb
12.2, which recognises specific repeat sequences present in K1 serotype parasites). The mAb recognizes the monomeric form of the MSP-1 hybrid
(,55 kDa dominant band) and a dimeric form of the antigen (,110 kDa band). Some degradation products are also detected by the mAb in all lanes,
but these are not detectable by silver staining (Panel A).
doi:10.1371/journal.pone.0026616.g002
Table 1. Yield and purity estimates from fed-batch fermentor production of the MSP-1 hybrid.
Whole Cell Pellet Lysate Post Heat Step Final Product
Total Protein (mg L
21) 11034 9291 2051 550.6
BB Hybrid Yield (mg L
21) 2282 2520 1724 550.6
Est. Product Purity % 21 27 84 .97
Total protein yields were calculated by BCA assay on samples from each purification step. The specific MSP-1 hybrid content in each sample was determined by
sandwich ELISA, using monoclonal 12.2 as a capture antibody and anti-MSP-1 hybrid polyclonal rabbit IgG as a detection reagent. MSP-1 hybrid content in samples from
each purification step was calculated by interpolation from a standard curve, using serial dilutions of purified MSP-1 hybrid as capture antigen. Purity and yield were
then calculated from these two measurements.
doi:10.1371/journal.pone.0026616.t001
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individual Block 2 antigens, which recognise the native MSP-1
antigen in Western blots and IFA, were also shown to recognize
the MSP-1 hybrid antigen in a specific and titratable manner
(Fig. 2B and data not shown).
Evaluation of immunogenicity and serotype specificity of
the MSP-1 hybrid
Mice were immunized with MSP-1 hybrid in five different
adjuvants suitable for use in humans, namely, aluminium
hydroxide (Alhydrogel, +/2 CpG 7909), Montanides ISA-51
and ISA-720 and CoVaccine HT. MSP-1 hybrid specific
antibodies were detected by ELISA in the sera of the majority of
immunized animals 14 days after the third dose, with median titers
in each group ranging from 1.9610
5 (Alhydrogel) to 8.9610
6
(CoVaccine HT) (Fig. 4A). Montanide ISA-720 and CoVaccine
HT gave the most consistent titers, with all animals producing
significant titers of antibodies above 1.5610
6. Antibody titers were
significantly higher in the CoVaccine HT group than all other
groups, with the exception of the Montanide ISA-720 group
(p,0.05 or less, Kruskal-Wallis test, Fig. 4A). In a single pairwise
comparison, the CoVaccine HT group had significantly higher
median titres than the Montanide ISA-720 group (8.9610
6
compared to 1.5610
6; Mann-Whitney U test, p=0.0027, Fig. 4A).
Individual mouse sera from the CoVaccine HT immunisation
group had broadly similar titers against individual K1-like type
(3D7, Palo Alto), MAD20-like type (MAD20, Wellcome) and
RO33 type antigens in most animals (Fig. 5A). However, some
mice (but not rabbits or monkeys immunized with the CoVaccine
HT formulation) selectively failed to respond to certain individual
Block 2 antigens (Fig. 5A and 5B). Similar results were obtained
for parasite-specific antibodies measured by immunofluorescence
(IFA) against parasites of the same five serotypes (data not shown).
Based on the strong immunogenicity of MSP-1 hybrid in mice
with five different adjuvant formulations, eight rabbits were then
immunized with purified MSP-1 hybrid formulated with CoVac-
cine HT, using a similar schedule to that used in mice, but at
50 mg per dose (see Materials and Methods). Seven animals
responded well to the immunisations, with one animal failing to
respond to any significant extent (Fig. 4B). Broad serum reactivity
against five recombinant MSP-1 Block 2 GST fusion proteins,
representative of all three Block 2 serotypes, was observed in all 7
responding animals (Fig. 5B).
As part of a pre-clinical proof of principle experiment, a group
of five Rhesus macaques (ranging 6.5 to 9.2 kg in body weight and
5.7 to 14.1 years of age at the time of first immunisations) were
immunized three times with 0.5 mL containing 50 mg of the MSP-
1 hybrid formulated in CoVaccine HT, using an identical protocol
to that used in rabbits (above). In this study, the vaccine was
delivered through the intramuscular route in alternating upper legs
(left, right, left) at 0, 4 and 8 weeks [Fig. 4C]. The choice of the
adjuvant for these studies was made on the basis that the adjuvant
has already been used as an investigational adjuvant in
clinical trials in humans (http://clinicaltrials.gov/ct2/show/
NCT01015703) and that the MSP-1 hybrid vaccine formulated
in CoVaccine HT was most effective in mice and rabbits (Figs. 4, 5
and above). The independent ethics committee at BPRC,
constituted according to Dutch law on animal experiments,
approved the study protocol (number DEC 598) prior to start of
the experiment. Again, strong and consistent immunogenicity was
elicited in all animals in response to the MSP-1 hybrid (Fig. 4C).
Increasing titers were observed with each dose (median titers:
day28, 6.9610
4; day56, 1.6610
5; day70, 5.8610
5). Encouraging-
ly, antibody reactivity against individual MSP-1 Block 2 antigens,
representative of the three Block 2 serotypes was also observed in
all animals, indicating that the vaccine elicits a broad serotype
antibody reactivity (median ELISA titers range from ,1.0610
5 to
,4.0610
5, Fig. 5C).
Fine-scale epitope mapping of antibody responses to
MSP-1 hybrid in immunized animals
A panel of 132 N-terminal biotinylated 12-mer peptides,
representative of all major linear epitopes in the Block 2 region
of MSP-1 were used to fine-scale map antibody responses in all
Figure 3. Stability analysis of purified MSP-1 hybrid protein. A. MSP-1 hybrid was incubated at 25uC for up to 60 days in liquid form in PBS,
pH 7.2. Silver stained SDS-PAGE gels were used to estimate degradation of the MSP-1 hybrid over time. The final 60-day time point did not show any
appreciable difference from the T0 sample. Lanes 1–12; samples taken at days 5,10,14,20,24,28, 30, 35, 42, 49, 56, and 60. B. MSP-1 hybrid samples
incubated at 25uC (Panel A) were subject to mass spectrometric analysis as described in Materials and Methods. A single predominant species at m/z
of ,1297 was detected, which remained unaltered in mass over the 60 day incubation in liquid form. A minor species at m/z of ,1292 is the MSP-1
hybrid minus its N-terminal methionine residue, a common modification which occurs to proteins expressed in E. coli [64].
doi:10.1371/journal.pone.0026616.g003
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known repetitive sequences from the K1 and MAD20 serotypes,
peptides from all non-repetitive regions of all three serotypes, and
a panel of 19 peptides covering the junctions between the
individual Block 2 serotypes. Due to the reduced sensitivity of this
assay with small volumes of available sera, animals that were
seronegative were not tested. In the remaining 25 mice, 6 rabbits
and 5 rhesus monkeys, reactivity with peptide epitopes was
observed across all three Block 2 serotypes, with some exceptions.
Generally, mice showed a more oligoclonal response to Block 2,
with a narrower number of reactivities, and with less broad
recognition of individual variant peptides (Fig. 6, panel A).
Figure 4. Immunogenicity and adjuvant testing of MSP-1 hybrid protein. A. Effect of adjuvants on antibody responses against MSP-1
hybrid. Groups of five or ten outbred MF1 mice were immunized s.c. three times at 4 week intervals with MSP-1 hybrid formulated with the adjuvants
as indicated on the X axis. Two weeks after the last immunization, serum samples were tested by ELISA for antibody responses against MSP-1 hybrid.
Titer was calculated as outlined in Materials and Methods. Data is shown on a log10 scale as dotplots of serum reactivity for individual animals with
the median level of Ab reactivity for each group indicated by a horizontal line. Horizontal brackets indicate statistically significant differences
between formulations as estimated by Kruskal-Wallis test. The asterisks represent statistical significance (*p,0.05, **p,0.01). B. Immunogenicity of
the MSP-1 hybrid in rabbits. A group of eight rabbits were immunized i.m. three times at 4 week intervals with MSP-1 hybrid formulated in CoVaccine
HT as described. At each immunization point, (d0, d28, d56) and two weeks after the last immunization (d70), serum samples from each animal were
tested by ELISA for antibody responses against MSP-1 hybrid. Titer was calculated as outlined in Materials and Methods. Data is shown on a log10
scale as dotplots of serum reactivity for individual animals with the median level of Ab reactivity for each group indicated by the solid line. C.
Immunogenicity of the MSP-1 hybrid in Rhesus monkeys. A group of five monkeys were immunized i.m. three times, at 4 week intervals with MSP-1
hybrid formulated in CoVaccine HT as described. At each immunization point, and two weeks after the last immunization (d70), serum samples from
each animal were tested by ELISA for antibody responses against MSP-1 hybrid. Titers were calculated as outlined in Materials and Methods. Data is
shown on a log10 scale as dotplots of serum reactivity for individual animals with the median level of Ab reactivity for each group indicated by the
solid line.
doi:10.1371/journal.pone.0026616.g004
Figure 5. Serotype specificity of antibody responses to MSP-1 Block 2 in animals immunized with MSP-1. Serum samples at day 70
from groups of animals immunized with MSP-1 hybrid formulated with CoVaccine HT were tested by ELISA for reactivity with Block 2 GST proteins of
different serotypes (K1 Block 2 serotype, 3D7 and Palo Alto; MAD20 serotype, MAD20 and Wellcome; RO33 serotype, RO33). ELISA titers were
calculated as described in Materials and Methods. Data is shown on a log10 scale as dotplots of serum reactivity for individual animals with the
median level of Ab reactivity for each group indicated by a horizontal line. A) Block 2 reactivity in immunized mice; B) Block 2 reactivity in immunized
rabbits; C) Block 2 reactivity in immunized Rhesus monkeys.
doi:10.1371/journal.pone.0026616.g005
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recognising epitopes from all three serotypes (Fig. 6, panel B).
Immunized rhesus monkeys showed antibody reactivity with
epitopes throughout all three Block 2 serotypes, and had
consistently fewer positive reactions with peptides containing
putative ‘‘neoepitopes’’ at the junctions between individual Block 2
serotype sequences (Fig. 6, Panel C). In these outbred animals,
there was no selective recognition of some epitopes rather than
others, which is consistent with our (unpublished) data and that of
others for Block 2 antibody reactivity in both animal and human
sera [37]. Peptides representing the junctions between the three
Block 2 serotypes, which would not occur in natural MSP-1
molecules were included in the 132 peptides tested, to detect any
responses directed against potential ‘neo-epitopes’ generated by
fusion of the three Block 2 serotypes within a single polypeptide
chain. Almost all antibody reactivity in individual serum samples
that showed reactivity with the ‘non-natural’ junctional peptides
was explained by antibody specificities to peptides from individual
‘natural’ Block 2 sequences.
Antigenicity in humans
Serum samples from a cross-sectional study conducted in
Burkina Faso in 2002 [38] were used to assess the antigenicity of
the MSP-1 hybrid in malaria-exposed individuals. Plasma samples
from a total of 90 and 55 children, aged ,10 years, were collected
from Fulani and Mossi ethnic groups respectively. These samples
were collected under ethical clearance from the Centre National
de Recherche et Formation sur le Paludisme (CNRFP), Ouaga-
dougou. We also included as negative controls 12 serum samples
from European blood donors who had not been exposed to
malaria.
As shown in Figure 7A, IgG antibodies from these children
specifically recognized the MSP-1 hybrid, and this reactivity
correlated with the reactivity in each serum sample against
individual Block 2 antigens. Negative control sera did not
recognize the protein (data not shown). Of the 145 plasma
samples tested, the majority of MSP-1 Block 2 positive sera
showed as strong or stronger antibody reactivity with the MSP-1
hybrid protein as was observed with any single serotype MSP-1
Block 2 antigen. This antibody reactivity with the MSP-1 hybrid
correlated closely with the maximum reactivity against any single
Block 2 antigen (Spearman’s Rho=0.7881, p,0.0001).
Sera from a cohort of Ghanaian children who were part of a
seroepidemiological survey of malaria incidence and immune
responses [25] were also tested for reactivity with the MSP-1
hybrid. This cohort was clinically and parasitologically monitored
for malaria episodes in a period lasting up to 500 days post
sampling [25]. It was clear that children with antibodies reactive
with the MSP-1 hybrid were significantly less likely to experience a
clinical malaria episode during the follow-up period, compared to
those who were seronegative for MSP-1 hybrid reactivity (Fig. 7B).
Survival analysis using Cox’s proportional hazards regression
model revealed a clear association between IgG to the MSP-1
hybrid and the time free from malaria (Exp(B)=0.484, p=0.006).
However, when age was included as a covariate in the analysis,
this association was marginally weaker (Exp(B)=0.642, p=0.098).
Parasite growth inhibition assays
In vitro parasite growth inhibition assays were used to assess one
functional activity of antibodies against P. falciparum parasites.
Using purified IgG from final bleed sera, taken from rabbits, sheep
and rhesus monkeys, antibodies were tested at a range of
concentrations against a number of different parasite strains.
Figure 8 shows results from these assays.
Although seven of the eight immunized rabbits responded well
to the vaccine, purified IgG from all animals failed to substantially
inhibit parasite growth in vitro, even at the highest concentration
(6 mg mL
21) of IgG (median inhibition 25.3%, range 12.4% to
33.0%, Fig. 8, panel A). Similarly, purified IgG from the four
immunized rhesus monkeys were also non-inhibitory at both
10 mg mL
21 and 5 mg mL
21 in GIA (median inhibition
212.9%, range 226.5% to 8.8%, Fig. 8, panel B). This was in
contrast to the high levels of inhibition seen in both assays by the
control standard rabbit IgG raised against seven different variants
of AMA-1 (EMVDA GIA standard, batch No. BG98, from
BPRC, Netherlands). By contrast, significant growth inhibition
was observed using polyclonal IgG purified from sheep immunized
with the MSP-1 hybrid (mean inhibition across three parasite
strains 51.2% at 6 mg mL
21 IgG, range 36.2% to 63.0%, Fig. 8,
panel C). Naı ¨ve pre-immunization IgG from the same animal
showed little or no growth inhibitory effect, and the low inhibition
observed showed no titratable effects (Fig. 8, Panel C, dashed line).
It must be noted that IgG from this animal was produced using
immunization with Freund’s adjuvant, and therefore may have a
more inhibitory effect due to higher affinity and/or broader
specificity, or may be an artifact of the species of antibody itself,
which has not been routinely used for parasite growth inhibition
assays. These assays of parasite growth inhibition are reproducible
in our hands and in the case of the anti-MSP-1 hybrid rabbit IgG
used here (Figure 8, Panel A), there is good correlation between
the data produced in our laboratory and that of BPRC, which also
tested the same samples (Figure 8, Panel D, R
2=0.844).
Discussion
This paper reports the expression of a soluble recombinant
protein (MSP-1 hybrid) which encompasses the sequence and
antigenic diversity present within the majority of MSP-1 Block 2
alleles found within the P. falciparum parasite population. A codon-
optimised construct was designed to include the known allelic
diversity in MSP-1 Block 2, using all polymorphic Block 2
sequences known to be the recognised by human and mouse
antibodies elicited by natural infection and immunisation
respectively. MSP-1 hybrid contains diverse B cell epitope
sequences derived from all three Block 2 serotypes, plus the N-
terminal MSP-1 Block 1 sequence known to contain human T cell
epitopes [34,35]. The recombinant protein was expressed with
high yield and was purified to homogeneity using a simple three-
step process, which was shown to be easily scalable. Promisingly,
MSP-1 hybrid yields at fermentor scale and the purity of the final
product were comparable to those achieved from shaking flask
cultures.
Expression of this hydrophilic, polar domain of MSP-1 in the
heterologous host E.coli was straightforward, as this region of the
MSP-1 gene lacks disulphide bonds and has a low frequency of
hydrophobic residues within its amino acid sequence. The
production of any construct based on Block 2 sequences is
therefore not constrained by disulphide bond formation or the
need for complex folding or refolding conditions in production, as
Block 2 sequences are intrinsically unstructured protein domains,
due to their unusual amino acid content [39,40]. Codon
optimisation of the MSP-1 hybrid construct also enabled even
higher-level expression than has been seen with non-optimised
Block 2 proteins [41]. Intrinsically unstructured proteins (IUPs)
have several unique properties, conferred on them by their
unusual amino acid composition, which includes high frequencies
of small hydrophilic amino acids. As IUPs have no hydrophobic
core, they do not lose solubility at elevated temperatures. Their
MSP-1 Hybrid Vaccine
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26616Figure 6. Recognition of peptide epitopes within the MSP-1 hybrid. A series of 133 N-terminally biotinylated dodecapeptides representing
the sequence diversity of all three Block 2 serotypes were used in ELISA to map the antibody specificities present in the sera of immunized animals.
Reactivity with individual peptides is shown as shaded boxes, with the depth of shading of each box representing the strength of reactivity of a
1:1000 dilution of sera with each peptide. The sequences and Block 2 serotype (K1, MAD20 and RO33) of each peptide are indicated down the right
hand side of the diagram.
doi:10.1371/journal.pone.0026616.g006
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PAGE. This means the apparent Mw of IUPs is often higher than
calculated from sequence data or determined by mass spectrom-
etry, and their lack of hydrophobic residues prevents efficient
binding by dyes such as Coomassie Blue [40]. The unstructured
flexible conformation(s) of the protein also makes fine-scale
mapping of a large number of B cell epitopes in these proteins
using peptide ELISA possible, which is not always the case for
globular proteins that possess more rigid conformational struc-
tures.
The thermostable nature of the MSP-1 hybrid also simplified
the development of a purification protocol for this vaccine, and
gave remarkable stability to the purified product, which remained
almost unaltered in liquid form (as estimated by mass spectrometry
and SDS-PAGE) over incubation periods of up to 60 days at 25uC
and 37uC. This contributes very positively to the suitability of the
MSP-1 hybrid as a malaria vaccine component, by removing the
requirement for a consistent cold chain.
Purified MSP-1 hybrid showed potent immunogenicity in mice
using five different human-compatible adjuvants. Despite its
relatively small size (31 kDa), MSP-1 hybrid elicited polyclonal
antibodies reactive with P. falciparum parasites of all three Block 2
serotypes in mice and rabbits. Furthermore, and very significantly,
the vaccine was also immunogenic in pre-clinical testing in non-
human primates. Three doses of MSP-1 hybrid formulated in
CoVaccine HT elicited potent immunogenicity in Rhesus
monkeys. Significantly, sera from animals immunized with the
MSP-1 hybrid display a broad reactivity with all three MSP-1
Block 2 serotypes in both IFA, ELISA and peptide mapping.
MSP-1 hybrid was consistently and reliably recognised by
African human serum antibodies and importantly by individual
human sera that contained single Block 2 specificities, as well as by
mouse monoclonal antibodies to Block 2 raised by immunisation
with parasite extracts. The antigenic integrity of the MSP-1 hybrid
indicates that this vaccine construct contains epitopes recognised
by antibodies from naturally exposed individuals and correlates
closely with the individual Block 2 reactivities seen in the same
serum samples using individual Block 2 antigens. In agreement
with previous studies showing that Block 2 epitopes are the target
of antibodies associated with protection from clinical malaria
[3,7,24,25], in this study antibodies to the MSP-1 hybrid showed a
clear association with reduced malaria incidence in a cohort of
Ghanaian children. Although the statistical significance of this
association was confounded by age, it remained close to
significance in a relatively small cohort (278 children) where Block
2 antibody positivity frequency is relatively low and where there
was a wide age range (3–15 years).
Antibodies to the MSP-1 hybrid raised by immunization in
rabbits and rhesus monkeys showed little growth inhibitory effect
in vitro in standard GIA. These are not unexpected results, as even
high titres of antibodies to several of the merozoite antigens have
also been shown to be non-inhibitory in GIA, primarily because
these antibodies are against antigens shed or non-covalently
associated with the parasite surface (e.g. MSP-2, MSP-3, GLURP)
[32,42,43,44]. These antigens however are targets of antibody
dependent cellular inhibition (ADCI), a property of such antigens,
including MSP-1 Block 2 [30].
Any sustained reduction in host mortality, morbidity and
parasite transmission will rely on a vaccine which targets multiple
antigens and multiple stages of the parasite lifecycle, thus
maximising the ‘‘hit’’ of any putatively effective vaccine. This is
clearly in line with the goals of Malaria Vaccine Technology
Roadmap, which includes the aim to ‘‘pursue multi-antigen, multi-
stage, and attenuated whole-parasite vaccine approaches’’ (www.
Figure 7. Recognition of MSP-1 hybrid protein by malaria-exposed human sera. A. Reactivity of human sera with MSP-1 hybrid. 145 serum
samples from children naturally exposed to malaria in Burkina Faso were tested for reactivity with the MSP-1 hybrid by ELISA. Sera were diluted 1:500
and tested against the five individual Block 2 GST fusion proteins described in Materials and Methods. For each individual serum sample, antibody
reactivity against the MSP-1 hybrid (X axis) is plotted against the maximum Ab reactivity seen against any one of the five individual Block 2 proteins
(Y axis). Marginally negative OD values on the Y axis are explained by high reactivity with GST alone in some sera. B. Association between antibodies
reactive with the MSP-1 hybrid and reduced incidence of clinical malaria in Ghanaian children over 500 days. Serum samples (diluted 1:500) from 278
children were tested by ELISA for antibody reactivity with the MSP-1 hybrid. Children were divided into those who were antibody positive (solid line,
n=68) or Ab negative (dashed lined, n=211) for the MSP-1 hybrid. Survival plots generated by Cox regression analysis of the proportions of children
who remained malaria free in the antibody-positive and antibody-negative groups are shown.
doi:10.1371/journal.pone.0026616.g007
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-page 4). Thus, development of any blood stage malaria vaccine
needs to address the issue of parasite antigenic diversity, as mono-
allelic vaccines have been shown to be ineffective [45] or effective
against only homologous parasite strains or serotypes [46,47].
Blood stage malaria parasite antigens are often polymorphic, and
this is now being addressed by development of vaccines containing
multiple forms of the same parasite antigen, to be delivered as
mixtures or as multimeric vaccine constructs [48,49,50]. Rather
than focus on conserved domains of candidate malaria vaccine
antigens, the MSP-1 hybrid addresses the issue of polymorphism
directly, by incorporating sequence and antigenic polymorphism
into a single protein vaccine product. The recent report that the
Block 2 region of MSP-1 is a target of antibody-dependent cellular
parasite inhibition activity in vitro [30] also supports the further
development of a blood stage vaccine based on MSP-1 Block 2. A
blood stage (and theoretically liver stage [19,20]) vaccine based on
the MSP-1 hybrid is supported by the evidence presented here,
Figure 8. P. falciparum growth inhibition assays (GIA) using purified IgG from MSP-1 hybrid immunized animals. Individual symbols
show percentage inhibition for IgG from each animal. The solid line indicates the median level of inhibition at each IgG concentration. In panels A and
B, the dotted line indicates inhibition obtained with an anti-AMA1 positive control rabbit IgG preparation (BG98 from BPRC Netherlands). A). Growth
inhibition using IgG from immunized rabbits and parasite strain 3D7. B) Growth Inhibition using IgG from immunized Rhesus monkeys and strain
NF54 C) Growth Inhibition using IgG from an MSP-1 hybrid immunized sheep using parasite strains Wellcome, RO33, and MAD20. Individual symbols
represent percentage inhibition of P falciparum strains Wellcome, RO33 and MAD20. Solid line; arithmetic mean of these values. Dashed line; growth
inhibition using purified naı ¨ve sheep IgG. D) Scatterplot comparing growth inhibition assay results from two independent laboratories. Data (from
panel A) generated at the University of Edinburgh plotted against data generated at BPRC, Netherlands using identical rabbit IgG preparations. The
relationship between the datasets was assessed by linear regression and the line of best fit is plotted as a solid line on the graph (Slope=1.25,
R
2=0.84).
doi:10.1371/journal.pone.0026616.g008
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immunogenicity in all three species of immunized animal,
especially in non-human primates, and the ability of the antigen
to elicit serotype spanning immune responses recognising multiple
parasite strains. A vaccine targeting the extensive antigenic
polymorphism of P. falciparum could substantially aid in achieving
the goals of the Global Malaria Action Plan.
Materials and Methods
Ethics statement
All mouse experimentation was carried out in accordance with
the Animals (Scientific Procedures) Act 1986 and conforms to the
Recommendation from the Declaration of Helsinki and the
Guiding Principles in the Care and Use of Animals. The
University of Edinburgh Ethical Review Committee approved
the project license under which all mouse experimentation was
performed on 3rd July 2006, reference number PL 13-06. Mice
were humanely killed by Schedule 1 methods.
Rabbit housing and immunization were at BioGenes GmbH
(Berlin, Germany), and were in accordance with national and
international animal welfare regulations. Rabbit immunization at
this facility was under approval from NIH/OLAW (ID number
#A5755-01).
Rhesus monkeys used in this study were captive bred for
research purposes, and housed at the Biomedical Primate
Research Center, Rijswijk (BPRC). Animal care procedures at
BPRC are in compliance with Dutch law on animal experiments,
European directive 86/609/EEC, and with the ‘‘Standard for
Humane Care and Use of Laboratory Animals by Foreign
Institutions’’, identification number A5539-01, provided by the
Department of Health and Human Services of the US National
Institutes of Health (NIH). All work with Rhesus monkeys is
compliant with the recommendations of the Weatherall report
‘‘The use of non-human primates in research’’ (http://www.
acmedsci.ac.uk/images/project/nhpdownl.pdf). The independent
ethics committee at BPRC, constituted according to Dutch law on
animal experiments, approved the study protocol (number
DEC598) prior to start of the experiment. Venapunctures and
immunizations were performed on ketamine-sedated monkeys to
minimise animal stress. Every day animals were carefully observed
for their general health. A veterinarian was available at all times to
take appropriate action in the event that abnormalities were
observed. One animal failed to recover from sedation on day 56
and died due to causes not related to vaccination, as determined
by autopsy. During the course of the study all animals received a
variety of enrichment items (e.g. toys, food puzzles).
Design and production of MSP-1 hybrid construct
MSP-1 Block 2 sequences from laboratory strains, from field
isolates of P. falciparum and downloaded from Genbank were
analysed and were all confirmed to belong into three main
serotypes, designated K1 type, MAD20 type and RO33 type, after
representative parasite clones in each group. Parasites of both the
K1 and the MAD20 types have conserved but serotype-specific
flanking sequences enclosing a region containing various combi-
nations of tripeptide repeats. Parasites of the RO33 serotype were
relatively conserved and contained no repeat sequences, but had
some point mutations between isolates within the serotype.
On examination of the aligned protein sequences of the three
Block 2 types, plus our data from earlier ELISA-based
seroepidemiological surveys of African sera [6,7,25,33,
51,52,53,54], we designed Block 2 sequences containing synthetic
tripeptide repeat sequences in an arrangement similar to that
found in naturally occurring Block 2 alleles. We designed codon-
optimised synthetic versions of both the K1- and MAD20-
serotypes of Block 2, both longer than any of the naturally
occurring sequences, and containing all of the possible nonapep-
tide repeat combinations seen within the naturally occurring Block
2 sequences. We also included the type-specific flanking sequences
common to each Block 2 type. In addition, we had evidence from
previously published work [34,35] and from our own use of
computer-based predictive algorithms, that known and predicted
human T-cell epitopes exist within the flanking sequences of Block
2, in the junction region between Block 2 and Block 1, and in
Block 1 itself, but are not predicted to exist within the repeats
themselves. Since there are no known or predicted T cell epitopes
wholly within the Block 2 region itself, and on the basis of earlier
immunogenicity testing, we included the Block 1 sequence in the
construct to provide cognate T cell help. The final construct
consisted of an upstream sequence corresponding to the K1 MSP-
1 Block 1 DNA fragment followed by the 3 main variants of the
Block 2 derived from Block 2 sequences from K1, RO33 and
MAD20 serotypes respectively (Fig. 1). The synthetic gene, called
MSP-1 hybrid, encodes a 348 amino acid protein with a predicted
molar mass of 31.1 kDa. This gene was synthesised by GeneArt
AG, Regensburg, Germany and cloned into the pET24a
expression vector (Novagen, UK).
Flask-based MSP1 hybrid protein expression
The expression plasmid was transformed into chemically
competent BL21 (DE3) pLysS E. coli (Agilent Technologies Ltd,
Stockport, UK) and plated on LB agar plates containing
50 ug mL
21 kanamycin. Starter cultures of 10 mL LB broth
containing 50 ug mL
21 kanamycin and 0.5% w/v L-glucose were
inoculated with a single colony from a freshly streaked agar plate.
Erlenmeyer flasks containing 1 litre LB broth, 0.5% w/v L-glucose
and 50 ug mL
21 kanamycin were inoculated with 5 mL starter
culture. Culture growth was monitored until the optical density
reached 0.6 AU cm
21, then protein production was induced by
addition of IPTG to 1 mM final concentration. Cultures were
incubated for a further 4 hours shaking at 30uC then cells were
harvested by centrifugation at 50006G and 4uC for 15 minutes.
Cell pellets were stored frozen at 280uC until further processing.
Fed batch MSP1 hybrid protein expression
A 15-litre stirred bioreactor (Applikon Technologies, UK) was
filled with 8 litres of modified YT medium. pH control was set to
maintain pH at 7.2 by addition of 4N H2SO4 or 30% v/v
NH4OH. Dissolved oxygen was monitored and maintained at
20% by manually increasing air flow or agitation speed, and
temperature was maintained at 37uC. The bioreactor was
inoculated by addition of 2% v/v starter culture and culture
density was monitored throughout the experiment by measure-
ment of optical density (OD) and wet pellet mass. Upon reaching
an OD of 1.2 AU cm
21, batch feeding commenced by pumped
addition of feed medium at an initial rate of 6.48 mL L
21 h
21
with an exponential increase in feeding rate (m=0.1 h
21). Protein
expression was induced by addition of 1 mM final concentration
of IPTG once a wet pellet weight equivalent to 75 g L
21 was
achieved. Fermentation continued for a further 4 hours with the
continued maintenance of parameters as described above. Cells
were harvested by centrifugation at 50006 G and the cell pellet
was stored in aliquots at 280uC until further processing.
Lab Scale Antigen Purification
Cell pellets from flask culture were ruptured by freeze-thaw lysis
in 25 mM Tris 250 mM NaCl pH 8.0, treated with 1 U ml
21 of
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and heated to 70uC for 20 minutes in a heated water bath. The
solution was incubated at 4uC for a further 20 minutes and
precipitated proteins removed by centrifugation at 50006 G for
30 minutes. The recovered solution was dialyzed extensively
against 25 mM Tris buffer pH 8.0, and anion exchange
chromatography carried out using a 25 mL Q Sepharose XL
column (GE Healthcare, UK). A step gradient of 20 mM NaCl in
25 mM Tris pH 8.0 was used to remove contaminants before
elution using 50 mM NaCl in 25 mM Tris pH 8.0. Retained
fractions containing the hybrid protein were pooled, dialyzed
against PBS and concentrated by centrifugal ultrafiltration using a
10 K cutoff Amicon concentrator (Millipore, UK) before being
heat treated at 70uC for storage at 220uC. The final purified
protein antigen concentration was measured by BCA assay
(Pierce, UK).
Antigen Purification from fed batch culture
Cell pellets from fed-batch fermentation were resuspended in
10 mL g
21 25 mM Tris pH 8.0 and ruptured by freeze-thaw lysis.
The lysate was treated with 2 U ml
21 of DNAse (Benzonase,
Novagen, UK), incubated for 30 minutes at room temperature
then heated to 90uC by passage through a 250 mL stainless steel
heat exchanger with a 20 minute residency time. The solution was
cooled to 4uC and precipitated proteins were removed by
centrifugation at 50006G for 30 minutes. The recovered solution
was dialyzed extensively against 25 mM Tris pH 8.0 buffer, and
anion exchange chromatography carried out using a chromatog-
raphy column containing 200 mL Capto Q bioprocess grade
sepharose (GE Healthcare, UK). Column chromatography and
further downstream processing were performed as described for
the lab-scale purification method.
SDS-PAGE, Silver staining and Western blot
Bacterial lysates, purification samples and purified MSP-1
hybrid were resolved by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) [55] and gels stained with silver
nitrate [56], as MSP-1 hybrid does not stain with Coomassie Blue.
The proteins separated by SDS-PAGE were electrophoretically
transferred to Schleicher and Schuell BA83 nitrocellulose
membranes (Whatman, UK). Membranes were blocked for 1 h
using nonfat milk in PBS containing 0.05% Tween 20 (PBS-T),
and then probed using antibody mAb 12.2, which specifically
recognises the K1-type allele of MSP-1 Block 2 [57]. After
washing, horseradish peroxidase-labeled anti-mouse IgG (Dako,
UK) was added for 1 h. The blots were washed and developed
with 0.6 mg mL
21 4-chloronapthol/0.003% H2O2. For stability
testing, aliquots of purified MSP-1 incubated at 25uC were
removed at various time intervals and then stored at 220uC before
analysis by SDS-PAGE and silver staining.
Protein analysis, estimation of purity and stability testing
Samples of the MSP-1 hybrid protein from each step of
purification were tested for purity and protein identity using SDS-
PAGE, ELISA and Western blotting. ImageJ image analysis
software was used to calculate percentage purity of protein samples
on SDS-PAGE by densitometry.
For stability testing, samples were heat treated at 70uC for
20 minutes and stored at 270uC, 220uC, 4uC, 25uC and 37uC
with sampling for up to 60 days. All time point samples were
resolved by SDS-PAGE and stained by silver staining to assess
degradation. Molecular weight and pI of the MSP-1 hybrid
protein was predicted using the ExPASy ProtParam tool (http://
www.expasy.ch/tools/protparam.html) based on its amino acid
sequence.
Mass spectrometry
Mass spectrometric analysis of the purified MSP-1 hybrid
protein was carried out by the SIRCAMS (Department of
Chemistry, University of Edinburgh, http://www.sircams.ed.ac.
uk). For LC-MS, an Ultimate 3000 HPLC system (Dionex
Corporation, Sunnyvale, CA), equipped with a monolithic PS-
DVB (500 mM65 mm) analytical column (Dionex Corporation),
was used. Samples containing ,1 mg of protein were centrifuged
(16,1006 G for 2 min) immediately prior to injection onto the
column. Solutions B and C comprised of 2:97.95 and 80:19.95
actonitrile:water with 0.05% formic acid respectively. Samples
were injected onto the analytical column, washed with buffer B for
5 min, followed by a 20 min linear gradient elution (20 mL/min)
into buffer C. MS data was acquired on a Bruker 12 Tesla Apex
Qe FT-ICR (Bruker Daltonics, Billerica, MA) equipped with an
electrospray ionization source. Desolvated ions were transmitted to
a 6 cm Infinity cellH penning trap. Trapped ions were excited
(frequency chirp 48–500 kHz at 100 steps of 25 ms) and detected
between m/z 600 and 2000 for 0.5 s to yield a broadband 512
Kword time-domain data. Fast Fourier Transforms and subse-
quent analyses were performed using DataAnalysis (Bruker
Daltonics) software. Multiple charge states could be observed in
this way for each of the major species.
MSP-1 Block 2 production, formulation and
immunizations
For immunogenicity studies on a single MSP-1 Block 2 protein
derived from the FVO MSP-1 sequence, purified GST Block 2
protein was prepared as previously described [33]. To determine
the immunogenicity of the FVO Block 2 protein alone, the FVO
Block 2 sequence was cleaved from GST-FVO Block 2 fusion
protein by incubation with thrombin at 37uC for 1 hour. FVO
Block 2 was purified from residual GST-FVO Block 2 and GST by
passage of the proteolytically cleaved material over a GSTrap
(Glutathione Sepharose) column five times. The resulting material
was then centrifuged through a Vivaspin 6 centrifugal concentra-
tor with 10,000 Da cutoff membranes to remove thrombin
(36 kDa) and any potential residual GST (28 kDa). The resulting
FVO Block 2 protein was used in immunogenicity studies in
comparison with the GST-FVO Block 2 protein from which it was
derived.
Outbred MF1 mice or inbred CBA/Ca mice (5 per group,
female) were immunized s.c. at 2 sites with either a) MSP-1 FVO
Block 2 protein or b) GST-FVO Block 2 formulated with
Alhydrogel (Brenntag Biosector, Denmark). For each mouse,
200 mL volumes containing 50 mg protein antigen in 0.32%
Alhydrogel were used for each dose. Each dose contained 0.16 mg
Al
3+. Groups of five mice were also immunized with the same
doses of each antigen, but formulated by emulsification with
Montanide ISA51 adjuvant (ratio 1:1) (Seppic, France), following
the manufacturer’s formulation instructions. For all groups of
mice, three doses were given at 28 day intervals, the animals were
exsanguinated at day 70 and serum prepared from each.
MSP-1 hybrid antigen formulation and immunizations
Purified sterile MSP-1 hybrid protein antigen was used as the
immunogen in the following immunization studies.
1. Outbred female MF1 mice (5 per group) were immunized s.c.
with the MSP-1 hybrid formulated with Alhydrogel (Brenntag
Biosector, Denmark). For each mouse, 100 mLv o l u m e s
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adjuvant alone or b) in combination with 10 mg/mL of CpG
7909 were used for each dose. Each dose contained 0.16 mg
Al
3+. Groups of five mice were immunized with the same doses
of MSP-1 hybrid formulated by emulsification with c)
Montanide ISA51 adjuvant (ratio 1:1) and d) Montanide
ISA720 (ratio 7:3) (Seppic, France), following the manufactur-
er’s formulation instructions. A group of ten mice were
immunized with the same dose of MSP-1 hybrid formulated
in e) CoVaccine HT
TM (Protherics Medicines Development
Limited, A BTG International Group Company, London, UK)
following the manufacturer’s instructions and as previously
described [58]. CoVaccine HT contains 40 mg mL
21 of
Sucrose Fatty Acid Sulphate Esters [SFASE] in a squalane
o/w emulsion). A 100 mL vaccine dose contained 20 mgo f
antigen and 2 mg of SFASE. For all groups of mice, three doses
were given at 28 day intervals contemporaneously, the animals
were exsanguinated at day 70 and serum prepared from each.
2. Eight New Zealand White rabbits were immunized intramus-
cularly, using 50 mg per dose of MSP-1 Hybrid antigen
formulated with CoVaccine HT following the manufacturer’s
instructions. A 500 mL vaccine dose contained 50 mg of antigen
and 10 mg of SFASE. Each animal was immunized 3 times at
28 day intervals, with blood samples taken at days 0, 28, 56 and
70. Rabbit housing and immunization were at BioGenes
GmbH (Berlin, Germany), and were in accordance with
national and international animal welfare regulations. Rabbit
immunization at this facility was under approval from NIH/
OLAW (ID number #A5755-01).
3. Five Rhesus macaques were immunized by BPRC, Rijswijk,
Netherlands, using 50 mg per dose of MSP-1 Hybrid antigen
formulated with Covaccine HT following the manufacturer’s
instructions and as previously described for formulation of P.
falciparum apical membrane antigen 1 (AMA-1) [58]. Each
animal was immunized 3 times with 0.5 mL volumes
containing 10 mg SFASE at 28-day intervals in alternating
legs (left, right, left), with blood samples taken at days 0, 28, 56
and 70.
Monoclonal and polyclonal antibodies
Mouse monoclonal and polyclonal antibodies for which specific
MSP-1 Block 2 epitopes had been confirmed in earlier studies
[33,59] were used for characterisation of the MSP-1 hybrid by
ELISA and Western blotting. Sera from 145 children from
Burkina Faso who lived in an area of seasonal malaria incidence
[38] were used to test the antigenicity of the MSP-1 hybrid by
ELISA. Samples of 278 Ghanaian children whose clinical malaria
status was known were originally collected for seroepidemiological
studies [25,26,60]. Control sera of malaria-naive Europeans were
taken from donors at the Scottish Blood Transfusion Service.
Antibody Purification
Immunoglobulin G from immunized animal sera was purified
on an A ¨kta Prime
TM chromatography system using HiTrap
protein G columns, according to the manufacturer’s recom-
mended protocols (GE Healthcare). Control IgG antibodies were
purified from naı ¨ve animals, or from day 0 (pre-immunization)
animals for Rhesus monkeys.
Parasite culture and growth inhibition assays
In vitro parasite growth Inhibition assays (GIA) were carried out
on freshly thawed clones of P. falciparum Wellcome or FCR3 strains
according to standard protocols [61,62], using purified IgG from
MSP-1 hybrid-immunized animals. Total IgG purified from a
naı ¨ve non-immunized animals were used as negative controls, or
from day 0 (pre-immunization) serum samples in the case of
Rhesus macaques. Rabbit IgG GIA was performed independently
at both BPRC and at the University of Edinburgh.
All IgG samples were tested in triplicate at 2-fold serial dilutions,
from 6 mg mL
21 (rabbit, sheep) or from 10 mg mL
21 (Rhesus) in
96-well cell culture plates (Greiner BioOne, UK). Parasites were
cultured under standard conditions [63]. Parasite cultures were
mycoplasma-free and synchronized at least twice with 5% sorbitol
before use in assays. Late trophozoite/early schizont stages at a
parasitaemia of 0.360.1% and 2% final haematocrit were used in
all assays. The final culture volume was 100 mL/well and parasites
were incubated for 42 h. After 42 hours, cultures were tested for
growth inhibition using pLDH measurement, flow cytometry and
Giemsa-stained slide microscopy. The data is presented as the
arithmetic mean percentage inhibition from each tested sample.
Antigens and Enzyme-Linked Immunosorbent Assay
(ELISA)
Individual MSP-1 recombinant proteins based on the 3D7, Palo
Alto, MAD20, Wellcome and RO33 MSP-1 Block 2 serotypes
have been described elsewhere [25,33]. These GST fusion proteins
and purified MSP-1 hybrid were used for ELISA analysis of Block
2 serotype reactivity.
Human sera, monoclonal antibodies and sera from MSP-1
hybrid immunized animals were tested by previously described
ELISA for recognition of the MSP-1 hybrid and Block 2 GST
fusion proteins [33] [51]. Negative control wells in ELISA were
either coating buffer alone for the MSP-1 hybrid, or GST-coated
wells for Block 2 GST fusion proteins. All sera were tested across a
range of doubling dilutions (1:1000 to 1:128,000) against each
antigen in duplicate wells, with a standard pool of Block 2 positive
sera also tested on the each plate, and across the same dilution
range. ELISA titers (arbitrary units) were calculated by interpo-
lation from the fitted standard curve on each plate using
polynomial logistic regression.
ELISA with biotinylated peptides
A set of 133 biotinylated dodecapeptides covering all possible
linear epitopes contained within MSP-1 hybrid sequence were
synthesised by Mimotopes Pyt. Ltd. (Clayton, Australia). ELISA
plates (Immulon 4 HBX, Thermo Dynex) were coated with
100 mLo f5mgm l
21 streptavidin (Sigma) and incubated at 37uC
until dry. Plates were stored in heat sealed foil pouches with 1 g
silica gel at room temperature until use. Reactivity of sera against
the peptide library was determined by ELISA. Streptavidin-coated
plates were washed in PBS-T (PBS/0.05% Tween20) and blocked
with blocking buffer (1% ByCoA, Croda Healthcare, UK dissolved
in PBS) for 5 hours at room temperature. Peptide library plates
were prepared by addition of 300 ng peptide per well, in duplicate,
and plates were incubated overnight at 4uC. Sera were added to
each well (100 uL at 1:500 dilution) and incubated overnight at
4uC, then washed with PBS-T. Dilutions of a species-specific
HRP-linked secondary antibody (Dako, UK), appropriate to the
serum being tested, were added to each well and plates were
incubated at room temperature for 3 hours. Plates were washed
three times with PBS-T and OPD substrate was added to each
well. Reactions were stopped by addition of sulfuric acid and
absorbance was read at 492 nm using a microplate absorbance
reader (Multiskan Ascent, Thermo Scientific, UK). Background
reactivity was calculated as the mean of all OD values in the lowest
two quartiles (i.e. below median)+6 standard deviations. Peptide
MSP-1 Hybrid Vaccine
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high=background +1 OD, medium=background +0.5 OD,
low=greater than background, negative=below background.
Indirect immunofluorescence assays (IFA)
Serum samples from mice immunized with MSP-1 Block 2 were
analyzed by IFA for parasite reactivity with the Wellcome isolate
of P. falciparum by methods previously described [33]. Wellcome
strain was chosen for IFA as it has an identical Block 2 sequence to
the FVO isolate. Endpoint titers were calculated as the highest
dilution at which clear antibody reactivity with schizont stage
parasites could be observed under FITC fluorescence.
Statistical analysis
For comparisons between ELISA titres in groups of immunized
animals, the data were analysed using the non-parametric
Kruskal-wallis test, with Dunn’s post-test. For comparisons
between two immunization groups, the Mann-Whitney U test
was used. For correlation plots of human antibody reactivity to
Block 2 versus the MSP-1 hybrid, Spearman’s rank correlation
coefficient was used. Survival analysis of the time to clinical
malaria in Ghanaian children was performed by Cox’s regression
analysis. In all cases, p values,0.05 were considered statistically
significant. Plots and analysis were prepared with either the Prism
graphical and statistics package (GraphPad Software, Inc., La
Jolla, USA), SPSS version 18 (SPSS Inc, Chicago, USA) or the R
statistical language (http://www.R-project.org).
Supporting Information
Figure S1 IFA titres of sera from mice immunized with
either GST-FVO Block2 fusion protein or FVO Block 2
alone. Sera were tested by IFA against the Wellcome P. falciparum
strain (identical Block 2 sequence to FVO). Hollow symbols, CBA
mice; filled symbols, MF-1 mice. Circles, GST-FVO Block 2
immunized mice; squares, FVO block 2 immunized mice.
Horizontal bars mark the median IFA titre for each group.
(TIF)
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